Trial intelligence / Profile preview

Concurrent versus sequential aromatase inhibitors with adjuvant chemotherapy in endocrine-responsive early breast cancer

2013-001629-23Phase 3Active

Sponsor: IRCCS Ospedale Policlinico San Martino
Start: Jun 2013
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
Countries: 1

Overview

Phase 3, randomised, open-label trial of anastrozole, letrozole and exemestane in breast cancer (2 arms), sponsored by IRCCS Ospedale Policlinico San Martino. Primary endpoint: Disease-free survival. Started Jun 2013; status: active.

Drugs

anastrozoleletrozoleexemestane

Conditions

breast cancer

Beyond the preview

Go deeper on 2013-001629-23.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2013-001629-23.